GlassScriptPhysician profile
Jay A Geary
NPI 1821071036
$5,103.56
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $1,424 · 2021: $1,893 · 2022: $1,053 · 2023: $19.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $737.39 | 2019-2022 | |
| Lilly USA, LLC | $603.73 | 2019-2022 | |
| Abbvie INC. | $452.79 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $427.74 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.33 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $284.56 | 2020-2022 | |
| Glaxosmithkline, LLC. | $260.29 | 2020-2023 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $257.37 | 2019-2022 | |
| Amgen INC. | $182.03 | 2019-2022 | |
| Allergan, INC. | $144.07 | 2020 | |
| Arbor Pharmaceuticals, INC. | $124.14 | 2019-2021 | |
| Eisai INC. | $124.06 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $123.73 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $100.86 | 2020-2022 | |
| Mylan Specialty L.P. | $84.76 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $82.56 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $81.67 | 2020-2021 | |
| Pfizer INC. | $75.46 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $71.73 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.63 | 2021-2022 | |
| Abbott Laboratories | $62.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $57.21 | 2021-2022 | |
| Shire North American Group INC | $53.50 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $48.66 | 2021 | |
| Genentech USA, INC. | $40.40 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.51 | 2022 | |
| Vertiflex, INC. | $32.62 | 2019 | |
| Supernus Pharmaceuticals, INC. | $29.55 | 2022 | |
| Sanofi Pasteur INC. | $18.17 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.69 | 2020 | |
| Almatica Pharma LLC | $13.24 | 2021 | |
| Adlon Therapeutics L.P. | $13.07 | 2020 | |
| Zyla Life Sciences, INC. | $11.50 | 2019 | |
| Inogen, INC. | $11.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Geary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.